The vaccine protects children from rotaviruses, which are the leading cause of severe diarrhoea among infants and young children.
A bench of Chief Justice G Rohini and Justice Jayant Nath was also told that the vaccine was withdrawn from the US due to the number of side effects, but it was being sought to be included in the universal immunisation scheme of India.
The results of the Phase III clinical trials at Vellore had revealed around 581 instances of side effects, the petitioner, a doctor at St Stephen's Hospital here, told the court, which reserved its verdict after also hearing the side of the government.
Puliyel in his plea has also sought directions to the government to provide complete data of the multi-centre clinical trials of the vaccine.
Appearing for Puliyel, advocate Prashant Bhushan argued that trial was conducted between 2011-2013 at various places across the country, but its data was not disclosed.
Bhushan said that as per guidelines of World Health Organisation (WHO), results of clinical trials have to be put in the public domain without delay.
Additional Solicitor General (ASG) Sanjay Jain, who appeared for the government, contended that WHO guidelines say the results of the trials are to be disclosed, which was done. The guidelines were not binding and do not say that data has to be disclosed, he added.
Jain also said the vaccine, called Rotovac, was not only the first indigenously developed and manufactured vaccine in the country, but also cheap as one dose would cost only about Rs 60.
According to the government rotavirus diarrhoea kills more than one lakh children under the age of five in India every year, a claim which has been opposed by Puliyel.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
